Peer review published in UroToday!! Money is a coming just a little while longer!!
Health Discovery Corporation Announces Publication of Peer Reviewed Scientific Paper Demonstrating the Clinical Validity of the Four-Gene Prostate Cancer Test Licensed to Abbott, Quest Diagnostics and Clarient
Press Release
Source: Health Discovery Corporation
On Tuesday July 14, 2009, 9:15 am EDT
Buzz up! 0
Print
Companies: Abbott laboratoriesClarient, inc.Quest diagnostics inc.
SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company specializing in personalized medicine, announced today that its scientific paper entitled “A Four-Gene Expression Signature for Prostate Cancer Cells Consisting of UAP1, PDLIM5, IMPDH2, and HSPD1” has successfully completed the peer review process and has been approved for publication in the August issue of UroToday International Journal. This publication demonstrates the clinical validity of the four-gene prostate cancer test for identifying clinically significant prostate cancer licensed for commercialization by HDC to Abbott (NYSE: ABT - News), Quest Diagnostics (NYSE: DGX - News), and Clarient (NasdaqCM: CLRT).
Related Quotes
Symbol Price Change
ABT 46.30 +0.15
CLRT 3.48 +0.03
DGX 54.36 -0.32
HDVY.OB 0.04 +0.01
UroToday International Journal® is an open access, peer-reviewed, urology and urologic oncology publication. The most widely accessible online urology publication in the field, UroToday International Journal® publishes state of the art reviews, original research papers, mini reports, rapid communications and more, in all fields of urology and has published articles from authors in 22 countries from 4 different continents. This International Urology Journal reaches over 18,000 subscribers and many more online readers. The Editorial Board of UroToday International Journal® strives to provide rapid publication of important manuscripts to the widest possible audience worldwide.
“We are very pleased to have the validated scientific results of our new four-gene prostate cancer test peer reviewed and accepted for publication by this prestigious and internationally recognized urology journal,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “The HDC four-gene prostate cancer test for clinically significant prostate cancer accepted for publication in UroToday International Journal® is the crux of our recent worldwide license agreements with our commercialization partners including Abbott, Quest Diagnostics and Clarient.” Dr. Barnhill continued “Having a peer reviewed medical publication should greatly assist our commercialization partners in their efforts to provide validated scientific results to physicians worldwide wanting to provide this new novel prostate cancer test to their patients, especially timely in light of the recent negative press regarding the poor performance of the PSA test for prostate cancer.”
About Health Discovery Corporation
Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of personalized medicine. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.
About Clarient
Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company.
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.
Contact:
Health Discovery Corporation
Stephen D. Barnhill, M.D., 1-912-443-1987
sbarnhill@healthdiscoverycorp.com
www.healthdiscoverycorp.com
